|Amarantus Bioscience Holdings, Inc|
655 Montgomery Street
United States - Map
Amarantus BioScience Holdings, Inc., a biotechnology company, engages in discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis. Its lead therapeutic program Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) is a targeted therapeutic to address the underlying programmed cell death (apoptosis) associated with a range of devastating human disorders with a priority to identify drug able orphan indications, including Retinitis Pigmentosa. The companys principal products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimers disease; and Eltoprazine, a small molecule drug candidate, which is used for the treatment of Parkinsons disease medication Levadopa-Induced Dyskinesia and Adult Attention Deficit Hyperactivity Disorders that is in Phase II clinical trials. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinsons disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus Bioscience Holdings, Inc. in April 2013. Amarantus Bioscience Holdings, Inc. was founded in 2008 and is based in San Francisco, California.
|Mr. Gerald E. Commissiong ,
Chief Exec. Officer, Pres and Director
|Dr. John Wesley Commissiong Ph.D.,
Chief Scientific Officer, Director and Member of the Scientific Advisory Board
|Mr. Robert Lewis Harris ,
Compliance Officer, Independent Director, Chairman of Governance & Nominating Committee, Member of Compensation Committee and Member of Audit Committee
|Mr. Marc E. Faerber ,
VP of Financial Operations, Corp. Controller, Treasurer and Sec.
|Mr. Robert E. Farrell J.D., Esq.,
Chief Financial Officer
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|